Therapy-Related Acute Myeloid Leukemia with KMT2A-SNX9 gene fusion associated with a hyperdiploid karyotype after Hemophagocytic Lymphohistiocytosis

Therapy-related acute myeloid leukemia (t-AML) following treatment with topoisomerase-II (topo-II) inhibitors has been increasingly reported and accounts for about 6.8% of AML [1]. The t-AML is a causal effect of somatic alterations after cytotoxic chemotherapy and/or radiotherapy, or even exposure to agents, such as anthracyclines and topo-II inhibitors (e.g. epipodophyllotoxins). Etoposide – a podophyllotoxin derivative – induces DNA strand breaks by inhibiting the action of topo-II and it is used in combination with other chemotherapeutic agents as first-line treatment of a variety of malignancies as well as in hemophagocytic lymphohistiocytosis (HLH).

Source: Cancer Genetics and Cytogenetics - May 6, 2021 Category: Genetics & Stem Cells Authors: Ingrid Sardou-Cezar, Bruno A. Lopes, Francianne Gomes Andrade, Teresa Cristina Cardoso Fonseca, Teresa de Souza Fernandez, Patrizia Larghero, Regiana Quinto de Souza, Gisele Loth, Lisandro Lima Ribeiro, Carmen Bonfim, Elissa Santos Morgado, Rolf Marschale Tags: Short Communication Source Type: research